Eagle IP was honored to co-host the AIPLA Women in IP Global Networking Event in collaboration with the Hong Kong Science and Technology Parks Corporation (HKSTP).

This annual event, organized by the American Intellectual Property Law Association (AIPLA), took place simultaneously in over 40 cities worldwide. As the official Hong Kong host, Eagle IP welcomed a vibrant community of female leaders, innovators, entrepreneurs, and IP practitioners to the Science Park for an evening of shared experiences and professional growth.

We would like to thank HKSTP for their partnership and all the attendees who contributed to such an inspiring evening. At Eagle IP, we are proud to support the advancement of women in the field and look forward to continuing these vital conversations.

Our Past Events

Recommended Insights

How Smart is a "Skilled Person in the Art"?

11 April 2022
Let’s start with a riddle: can you name a person who has read every book, every journal, conducted every known experiment, and is knowledgeable about every single patent prosecution / litigation in the world? The answer? A “skilled person in the art.” This person is also known as a “person having ordinary skill in the […]

China’s Newest Examination Guidelines: Novelty and Inventive Step for Compounds (Part II)

29 April 2021
This is Part II of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

How to Protect a Crystal Form (Polymorph) Patent in China

4 June 2025
Crystalline forms are critical to pharmaceutical patents, offering extended protection for improved stability, bioavailability, or manufacturability. However, securing such patents in China has grown increasingly difficult due to the China National Intellectual Property Administration (CNIPA)’s strict patentability criteria. Unlike the U.S. or Europe, where structural novelty or problem-solving utility may suffice, China demands quantifiable evidence of […]

Breaking: China Released Drug Trial Data Protection Implementation Measures

22 May 2026
On May 15, 2026, China’s National Medical Products Administration (NMPA) officially announced the final Measures for the Implementation of Drug Trial Data Protection (“Measures”), effective May 15, 2026. These Measures provide important details supporting the recently announced Implementing Regulations of the Drug Administration Law (“Regulations” – also effective May 15, 2026), which formally introduced a […]
Top crossarrow-right